Compare HCA Health Inc (HCA) vs Revvity Inc (RVTY) Price & Performance

HCA Healthcare trades at $370.74, down 0.12% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and revenue growth to $75.6 billion in 2025. The stock faces headwinds from lowered 2026 guidance and negative news flow, but maintains a solid valuation with a P/E of 12.79 and positive analyst consensus.

The outlook is mixed: attractive valuation and operational strength support upside to the $469.40 price target, but near-term risks from payer mix shifts and legal investigations warrant caution. Long-term growth drivers include capacity expansion and medical advancements, though investor sentiment is currently pressured.

RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.

The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.